DKK1 and rheumatoid arthritis: Conversely, Fassio et al. recently found a rapid decline in both Dkk-1 and sclerostin serum levels in RA patients after 2 months of treatment with TNFα inhibitor certolizumab-pegol, accompanied by dramatic changes in bone turnover [43].